Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?

Overview

Journal Front Oncol

Specialty Oncology

Date 2019 Apr 4

PMID 30941314

Citations 43

Authors

Alex Friedlaender

Giuseppe Banna

Umberto Malapelle

Pasquale Pisapia

Alfredo Addeo

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the leading cause of cancer-related mortality and will affect ~6% of the population. It is divided into two broad categories, small cell lung cancer and non-small cell lung cancer (NSCLC), the latter representing 85% of all lung cancers. It mainly comprises adenocarcinoma (65%) and squamous cell carcinoma (30%) histologies. In recent years, there have been two major therapeutic advances in NSCLC. The first, immunotherapy, has greatly improved the prognosis of adenocarcinomas and squamous cell carcinomas. The second, the treatment of targetable driver mutations, has so far only benefited adenocarcinomas. Squamous cell carcinoma carries a high rate of mutations and is found mostly among smokers. This raises two important problems: identifying driver mutations and finding those of clinical relevance. Large-scale genomic analyses such as The Cancer Genome Atlas have allowed for the identification of frequent gene alterations, although their role and potential for targeted therapy remain unknown. The emergence of next generation sequencing has changed the landscape of precision medicine, in particular in lung cancer. In this review, we discuss the landscape of genetic alterations found in squamous cell lung cancer, the results of current targeted therapy trials, the difficulties in identifying and treating these alterations and how to integrate modern tools in clinical practice.

Citing Articles

MAP1LC3C repression reduces CIITA- and HLA class II expression in non-small cell lung cancer.

Barbeau L, Beelen N, Savelkouls K, Keulers T, Wieten L, Rouschop K PLoS One. 2025; 20(2):e0316716.

PMID: 39928678 PMC: 11809862. DOI: 10.1371/journal.pone.0316716.

Comprehensive review of LncRNA-mediated therapeutic resistance in non-small cell lung cancer.

Ge X, Shen Z, Yin Y Cancer Cell Int. 2024; 24(1):369.

PMID: 39522033 PMC: 11549762. DOI: 10.1186/s12935-024-03549-1.

Liquid and Tissue Biopsies for Lung Cancer: Algorithms and Perspectives.

Hofman P Cancers (Basel). 2024; 16(19).

PMID: 39409960 PMC: 11482622. DOI: 10.3390/cancers16193340.

Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions.

Garg P, Singhal S, Kulkarni P, Horne D, Malhotra J, Salgia R J Clin Med. 2024; 13(14).

PMID: 39064229 PMC: 11278207. DOI: 10.3390/jcm13144189.

Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study.

Sposito M, Belluomini L, Nocini R, Insolda J, Scaglione I, Menis J Front Oncol. 2024; 14:1436588.

PMID: 39045557 PMC: 11263796. DOI: 10.3389/fonc.2024.1436588.

References

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

Pepe F, De Luca C, Smeraglio R, Pisapia P, Sgariglia R, Nacchio M . Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples. J Clin Pathol. 2018; 72(1):38-45. DOI: 10.1136/jclinpath-2018-205386. View

Banna G, Passiglia F, Colonese F, Canova S, Menis J, Addeo A . Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection. Crit Rev Oncol Hematol. 2018; 129:27-39. DOI: 10.1016/j.critrevonc.2018.06.016. View

Pitz M, Eisenhauer E, MacNeil M, Thiessen B, Easaw J, Macdonald D . Phase II study of PX-866 in recurrent glioblastoma. Neuro Oncol. 2015; 17(9):1270-4. PMC: 4588751. DOI: 10.1093/neuonc/nou365. View

Landi L, Tiseo M, Chiari R, Ricciardi S, Rossi E, Galetta D . Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. Clin Lung Cancer. 2014; 15(6):411-417.e4. DOI: 10.1016/j.cllc.2014.07.002. View

Pennell N, Mutebi A, Zhou Z, Ricculli M, Tang W, Wang H . Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic Model. JCO Precis Oncol. 2022; 3:1-9. DOI: 10.1200/PO.18.00356. View

Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J . Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016; 387(10030):1837-46. DOI: 10.1016/S0140-6736(16)00587-0. View

Goss G, Felip E, Cobo M, Lu S, Syrigos K, Lee K . Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. JAMA Oncol. 2018; 4(9):1189-1197. PMC: 6143014. DOI: 10.1001/jamaoncol.2018.0775. View

Pilotto S, Rossi A, Vavala T, Follador A, Tiseo M, Galetta D . Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study. Clin Lung Cancer. 2017; 19(1):93-104. DOI: 10.1016/j.cllc.2017.05.016. View

10.

Dziadziuszko R, Wynes M, Singh S, Asuncion B, Ranger-Moore J, Konopa K . Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J Thorac Oncol. 2012; 7(2):340-7. PMC: 3358920. DOI: 10.1097/JTO.0b013e318240ca0d. View

11.

Yang J, Wu Y, Schuler M, Sebastian M, Popat S, Yamamoto N . Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015; 16(2):141-51. DOI: 10.1016/S1470-2045(14)71173-8. View

12.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X. View

13.

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

14.

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

15.

Gagan J, Van Allen E . Next-generation sequencing to guide cancer therapy. Genome Med. 2015; 7(1):80. PMC: 4517547. DOI: 10.1186/s13073-015-0203-x. View

16.

Hashemi-Sadraei N, Hanna N . Targeting FGFR in Squamous Cell Carcinoma of the Lung. Target Oncol. 2017; 12(6):741-755. DOI: 10.1007/s11523-017-0513-6. View

17.

Kong-Beltran M, Stamos J, Wickramasinghe D . The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell. 2004; 6(1):75-84. DOI: 10.1016/j.ccr.2004.06.013. View

18.

Gainor J, Shaw A, Sequist L, Fu X, Azzoli C, Piotrowska Z . EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res. 2016; 22(18):4585-93. PMC: 5026567. DOI: 10.1158/1078-0432.CCR-15-3101. View

19.

Lu Y, Lu K . Advancements in next-generation sequencing for diagnosis and treatment of non-small-cell lung cancer. Chronic Dis Transl Med. 2017; 3(1):1-7. PMC: 5627693. DOI: 10.1016/j.cdtm.2017.02.009. View

20.

Engelman J . Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9(8):550-62. DOI: 10.1038/nrc2664. View